Today, bluebird bio begins our next era as Genetix Biotherapeutics. Follow us Genetix Biotherapeutics. Our mission remains unchanged: transforming lives through curative therapies. What’s new is how we deliver on that mission—with a sharpened focus on commercial execution, scalability, and creating long-term impact for patients. Backed by new leadership, strengthened financial support, and a commitment to transparency, we’re investing in manufacturing, expanding our reach, and partnering with providers to improve every step of the treatment journey. Learn more about our mission here https://l.ead.me/bgJTwh. David Meek
bluebird bio
Biotechnology Research
Somerville, Massachusetts 139,949 followers
Pursuing curative gene therapies to give patients and their families more bluebird days.
About us
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines
- Website
-
http://www.bluebirdbio.com
External link for bluebird bio
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Somerville, Massachusetts
- Type
- Public Company
- Founded
- 1993
- Specialties
- gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy
Locations
-
Primary
Get directions
455 Grand Union Blvd
Somerville, Massachusetts 02145, US
Employees at bluebird bio
-
Mike Schwarz
Director QTC Account Lead @ bluebird bio | Commercial Expansion, Analytics, Key Opinion Leaders
-
Stephen Martin
Digital Marketing Technology Partner | Web • Strategy • CRM/CDP • Data Integration | Biotech & Healthcare
-
Bem Atsma
Director, Regulatory Affairs CMC at bluebird bio
-
Denise Schultz
Director, Regulatory CMC at bluebird bio
Updates
-
September is Sickle Cell Awareness Month. Throughout the month of September, you’ll see spotlights and reflections from sickle cell warriors and the bluebird team on our page. We’re excited to celebrate the sickle cell community and share why this mission matters so deeply to us. We invite you to follow along, join the conversation, and help amplify awareness for #sicklecelldisease. Together, we can turn awareness into impact.
-
-
Today bluebird bio announced a definitive agreement to be acquired by Carlyle and SK Capital. Read more in our press release: https://lnkd.in/eCg7cfTx
-
-
bluebird bio is presenting additional long-term follow-up data from gene therapy programs in sickle cell disease and beta-thalassemia at the 66th American Society of Hematology (#ASH24) Annual Meeting and Exposition. Learn more about the data being presented: https://lnkd.in/e4zJDECJ
-
bluebird bio will be at #ASH24 this weekend discussing our experience as a gene therapy leader and presenting data demonstrating the transformational impact of bluebird’s gene therapies for #betathalassemia and #sicklecelldisease. If you are on site, find a member of the flock and say hi!
-
Today, bluebird bio announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outcomes-based agreement for sickle cell gene therapy under the Cell and Gene Therapy (CGT) Access Model. “Ensuring timely, equitable access to gene therapy for people living with sickle cell disease insured through Medicaid has been a cornerstone of our commercial approach since approval, and we are pleased to build on this commitment by offering an outcomes-based agreement to state Medicaid agencies through the CGT Access Model. We are also pleased to be able to offer fertility preservation support to eligible patients insured by Medicaid in states that opt into the Model, as we recognize these services address an important potential barrier to access.” – Tom Klima, Chief Commercial & Operating Officer Learn more: https://lnkd.in/enaHNGqJ
-
The flock is excited to share that we are presenting additional long-term follow-up data from our gene therapy programs in sickle cell disease and beta-thalassemia at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition. Learn more: https://lnkd.in/etdQzevw
-
Congrats to Cooley's Anemia Foundation on 70 years of supporting the beta-thalassemia community. Thank you for everything you do for people living with beta-thalassemia and their families.